Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1996 Apr;55(4):237–242. doi: 10.1136/ard.55.4.237

Divergent effects of methotrexate on the clonal growth of T and B lymphocytes and synovial adherent cells from patients with rheumatoid arthritis.

A Nakajima 1, M Hakoda 1, H Yamanaka 1, N Kamatani 1, S Kashiwazaki 1
PMCID: PMC1010144  PMID: 8733440

Abstract

OBJECTIVE: To define the mechanisms whereby methotrexate (MTX) manifests its effects in patients with rheumatoid arthritis. METHODS: T and B cells from peripheral blood and rheumatoid synovial tissues, synovial adherent cells, and the human fibrosarcoma cell line HT1080 and its mutant (defective in an enzyme in the nucleotide salvage pathway) were tested for clonal growth when cultured with MTX. Normal human fibroblasts and those with a deficiency in a salvage pathway were cultured with MTX in the presence or absence of purine and pyrimidine bases. RESULTS: Clonal growth of T and B cells, but not synovial cells, was inhibited by clinically relevant concentrations of MTX. Slowly proliferating fibroblast lines were resistant to MTX, whereas their rapidly proliferating counterparts were not. However, mutant fibroblast lines deficient in a salvage pathway were sensitive to MTX despite slow proliferation. Similarly, while skin fibroblasts were resistant to MTX, germline mutant fibroblasts deficient in a salvage pathway were sensitive to small concentrations of MTX. CONCLUSION: T and B lymphocytes, but not synovial cells, may be the target of MTX in vivo. Resistance to MTX may be associated with slow proliferation and the ability to synthesise nucleotides via salvage pathways. MTX can inhibit proliferation of even slowly growing cells by restricting the supply of nucleotides obtained via a salvage pathway, by removal of purine and pyrimidine bases, or by inducing a deficiency in a salvage pathway. It may be possible to manipulate the therapeutic effect of MTX by adjusting the amounts of purines and pyrimidines available to the cells in vivo.

Full text

PDF
237

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahern M., Booth J., Loxton A., McCarthy P., Meffin P., Kevat S. Methotrexate kinetics in rheumatoid arthritis: is there an interaction with nonsteroidal antiinflammatory drugs? J Rheumatol. 1988 Sep;15(9):1356–1360. [PubMed] [Google Scholar]
  2. Alarcón G. S., López-Méndez A., Walter J., Boerbooms A. M., Russell A. S., Furst D. E., Rau R., Drosos A. A., Bartolucci A. A. Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients: a meta-analysis. J Rheumatol. 1992 Dec;19(12):1868–1873. [PubMed] [Google Scholar]
  3. Alarcón G. S., Schrohenloher R. E., Bartolucci A. A., Ward J. R., Williams H. J., Koopman W. J. Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis. Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression. Arthritis Rheum. 1990 Aug;33(8):1156–1161. doi: 10.1002/art.1780330816. [DOI] [PubMed] [Google Scholar]
  4. Allegra C. J., Drake J. C., Jolivet J., Chabner B. A. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci U S A. 1985 Aug;82(15):4881–4885. doi: 10.1073/pnas.82.15.4881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Alt F. W., Kellems R. E., Bertino J. R., Schimke R. T. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J Biol Chem. 1978 Mar 10;253(5):1357–1370. [PubMed] [Google Scholar]
  6. Andersen P. A., West S. G., O'Dell J. R., Via C. S., Claypool R. G., Kotzin B. L. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med. 1985 Oct;103(4):489–496. doi: 10.7326/0003-4819-103-4-489. [DOI] [PubMed] [Google Scholar]
  7. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
  8. Barrera P., Boerbooms A. M., Janssen E. M., Sauerwein R. W., Gallati H., Mulder J., de Boo T., Demacker P. N., van de Putte L. B., van der Meer J. W. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum. 1993 Aug;36(8):1070–1079. doi: 10.1002/art.1780360807. [DOI] [PubMed] [Google Scholar]
  9. Bologna C., Edno L., Anaya J. M., Canovas F., Vanden Berghe M., Jorgensen C., Galtier M., Combe B., Bressolle F., Sany J. Methotrexate concentrations in synovial membrane and trabecular and cortical bone in rheumatoid arthritis patients. Arthritis Rheum. 1994 Dec;37(12):1770–1773. doi: 10.1002/art.1780371210. [DOI] [PubMed] [Google Scholar]
  10. Buchbinder R., Hall S., Sambrook P. N., Champion G. D., Harkness A., Lewis D., Littlejohn G. O., Miller M. H., Ryan P. F. Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol. 1993 Apr;20(4):639–644. [PubMed] [Google Scholar]
  11. Chang D. M., Baptiste P., Schur P. H. The effect of antirheumatic drugs on interleukin 1 (IL-1) activity and IL-1 and IL-1 inhibitor production by human monocytes. J Rheumatol. 1990 Sep;17(9):1148–1157. [PubMed] [Google Scholar]
  12. Chang D. M., Weinblatt M. E., Schur P. H. The effects of methotrexate on interleukin 1 in patients with rheumatoid arthritis. J Rheumatol. 1992 Nov;19(11):1678–1682. [PubMed] [Google Scholar]
  13. Cronstein B. N., Eberle M. A., Gruber H. E., Levin R. I. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2441–2445. doi: 10.1073/pnas.88.6.2441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Cronstein B. N. Molecular mechanism of methotrexate action in inflammation. Inflammation. 1992 Oct;16(5):411–423. doi: 10.1007/BF00918968. [DOI] [PubMed] [Google Scholar]
  15. Cronstein B. N., Naime D., Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest. 1993 Dec;92(6):2675–2682. doi: 10.1172/JCI116884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Goto M., Sasano M., Yamanaka H., Miyasaka N., Kamatani N., Inoue K., Nishioka K., Miyamoto T. Spontaneous production of an interleukin 1-like factor by cloned rheumatoid synovial cells in long-term culture. J Clin Invest. 1987 Sep;80(3):786–796. doi: 10.1172/JCI113135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hakoda M., Ishimoto T., Hayashimoto S., Inoue K., Taniguchi A., Kamatani N., Kashiwazaki S. Selective infiltration of B cells committed to the production of monoreactive rheumatoid factor in synovial tissue of patients with rheumatoid arthritis. Clin Immunol Immunopathol. 1993 Oct;69(1):16–22. doi: 10.1006/clin.1993.1144. [DOI] [PubMed] [Google Scholar]
  18. Hakoda M., Ishimoto T., Yamamoto K., Inoue K., Kamatani N., Miyasaka N., Nishioka K. Clonal analysis of T cell infiltrates in synovial tissue of patients with rheumatoid arthritis. Clin Immunol Immunopathol. 1990 Dec;57(3):387–398. doi: 10.1016/0090-1229(90)90113-5. [DOI] [PubMed] [Google Scholar]
  19. Hanrahan P. S., Russell A. S. Concurrent use of folinic acid and methotrexate in rheumatoid arthritis. J Rheumatol. 1988 Jul;15(7):1078–1080. [PubMed] [Google Scholar]
  20. Herman R. A., Veng-Pedersen P., Hoffman J., Koehnke R., Furst D. E. Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J Pharm Sci. 1989 Feb;78(2):165–171. doi: 10.1002/jps.2600780219. [DOI] [PubMed] [Google Scholar]
  21. Jundt J. W., Browne B. A., Fiocco G. P., Steele A. D., Mock D. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol. 1993 Nov;20(11):1845–1849. [PubMed] [Google Scholar]
  22. Kremer J. M., Phelps C. T. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum. 1992 Feb;35(2):138–145. doi: 10.1002/art.1780350203. [DOI] [PubMed] [Google Scholar]
  23. Leroux J. L., Damon M., Chavis C., Crastes de Paulet A., Blotman F. Effects of a single dose of methotrexate on 5- and 12-lipoxygenase products in patients with rheumatoid arthritis. J Rheumatol. 1992 Jun;19(6):863–866. [PubMed] [Google Scholar]
  24. Li W. W., Lin J. T., Schweitzer B. I., Tong W. P., Niedzwiecki D., Bertino J. R. Intrinsic resistance to methotrexate in human soft tissue sarcoma cell lines. Cancer Res. 1992 Jul 15;52(14):3908–3913. [PubMed] [Google Scholar]
  25. Meyer F. A., Yaron I., Mashiah V., Yaron M. Methotrexate inhibits proliferation but not interleukin 1 stimulated secretory activities of cultured human synovial fibroblasts. J Rheumatol. 1993 Feb;20(2):238–242. [PubMed] [Google Scholar]
  26. Morgan S. L., Baggott J. E., Vaughn W. H., Young P. K., Austin J. V., Krumdieck C. L., Alarcón G. S. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 1990 Jan;33(1):9–18. doi: 10.1002/art.1780330102. [DOI] [PubMed] [Google Scholar]
  27. Nesher G., Moore T. L. The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation by methyl donors and spermidine. Arthritis Rheum. 1990 Jul;33(7):954–959. doi: 10.1002/art.1780330706. [DOI] [PubMed] [Google Scholar]
  28. Olsen N. J., Callahan L. F., Pincus T. Immunologic studies of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 1987 May;30(5):481–488. doi: 10.1002/art.1780300501. [DOI] [PubMed] [Google Scholar]
  29. Olsen N. J., Murray L. M. Antiproliferative effects of methotrexate on peripheral blood mononuclear cells. Arthritis Rheum. 1989 Apr;32(4):378–385. doi: 10.1002/anr.1780320404. [DOI] [PubMed] [Google Scholar]
  30. Rodenhuis S., Kremer J. M., Bertino J. R. Increase of dihydrofolate reductase in peripheral blood lymphocytes of rheumatoid arthritis patients treated with low-dose oral methotrexate. Arthritis Rheum. 1987 Apr;30(4):369–374. doi: 10.1002/art.1780300402. [DOI] [PubMed] [Google Scholar]
  31. Segal R., Caspi D., Tishler M., Wigler I., Yaron M. Short term effects of low dose methotrexate on the acute phase reaction in patients with rheumatoid arthritis. J Rheumatol. 1989 Jul;16(7):914–917. [PubMed] [Google Scholar]
  32. Segal R., Mozes E., Yaron M., Tartakovsky B. The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum. 1989 Apr;32(4):370–377. doi: 10.1002/anr.1780320403. [DOI] [PubMed] [Google Scholar]
  33. Shiroky J. B., Neville C., Esdaile J. M., Choquette D., Zummer M., Hazeltine M., Bykerk V., Kanji M., St-Pierre A., Robidoux L. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1993 Jun;36(6):795–803. doi: 10.1002/art.1780360609. [DOI] [PubMed] [Google Scholar]
  34. Sinnett M. J., Groff G. D., Raddatz D. A., Franck W. A., Bertino J. S., Jr Methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol. 1989 Jun;16(6):745–748. [PubMed] [Google Scholar]
  35. Sperling R. I., Benincaso A. I., Anderson R. J., Coblyn J. S., Austen K. F., Weinblatt M. E. Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheum. 1992 Apr;35(4):376–384. doi: 10.1002/art.1780350403. [DOI] [PubMed] [Google Scholar]
  36. Sperling R. I., Coblyn J. S., Larkin J. K., Benincaso A. I., Austen K. F., Weinblatt M. E. Inhibition of leukotriene B4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate. Arthritis Rheum. 1990 Aug;33(8):1149–1155. doi: 10.1002/art.1780330815. [DOI] [PubMed] [Google Scholar]
  37. Suarez C. R., Pickett W. C., Bell D. H., McClintock D. K., Oronsky A. L., Kerwar S. S. Effect of low dose methotrexate on neutrophil chemotaxis induced by leukotriene B4 and complement C5a. J Rheumatol. 1987 Feb;14(1):9–11. [PubMed] [Google Scholar]
  38. Tishler M., Caspi D., Fishel B., Yaron M. The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthritis Rheum. 1988 Jul;31(7):906–908. doi: 10.1002/art.1780310712. [DOI] [PubMed] [Google Scholar]
  39. Wascher T. C., Hermann J., Brezinschek R., Brezinschek H. P., Wilders-Truschnig M., Rainer F., Krejs G. J. Serum levels of interleukin-6 and tumour-necrosis-factor-alpha are not correlated to disease activity in patients with rheumatoid arthritis after treatment with low-dose methotrexate. Eur J Clin Invest. 1994 Jan;24(1):73–75. doi: 10.1111/j.1365-2362.1994.tb02063.x. [DOI] [PubMed] [Google Scholar]
  40. Weinblatt M. E., Coblyn J. S., Fox D. A., Fraser P. A., Holdsworth D. E., Glass D. N., Trentham D. E. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985 Mar 28;312(13):818–822. doi: 10.1056/NEJM198503283121303. [DOI] [PubMed] [Google Scholar]
  41. Williams H. J., Willkens R. F., Samuelson C. O., Jr, Alarcón G. S., Guttadauria M., Yarboro C., Polisson R. P., Weiner S. R., Luggen M. E., Billingsley L. M. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 1985 Jul;28(7):721–730. doi: 10.1002/art.1780280702. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES